What can be done to improve HTAs?
The biotech industry proposes the development of shared European standards for HTAs to ensure the highest level of transparency, dialogue and trust amongst stakeholders and public authorities – including social values, which are part of our solidarity-based healthcare systems and are the foundation of our European society. [top] Should HTAs include a broader perspective? Yes. HTA evaluations should include all relevant stakeholders and take place in the context of the whole budget for healthcare, and be equally made for processes, procedures, service costs and products. They should take account of issues such as the policy context, community need, alternative treatment, uniqueness, disease rarity, utilization patterns, cost-effectiveness, budget-impact, organization and staffing impact, future evidence that will become available, ethics, access and healthcare funding mechanisms within this framework, HTA may reach different conclusions on the same technology in different countries or r
